Abstract: A headrest is described having a vertically adjustable element, an adjustable lap rest, and a cup. The vertically adjustable element has a lower end and an upper end, where the vertically adjustable element has a height, h1, when fully extended and has a height, h2, when collapsed, where h2<h1. The adjustable lap rest element has a first portion that is attached to the lower end of the vertically adjustable element and has a second portion comprising a fold-out. The fold-out, in a horizontal configuration, functions as a lap rest and, in a vertical configuration, functions to increase the height of the headrest, when fully extended, from the height, h1, to height h1+h3. The cup is attached to the upper end of the vertically adjustable element, where the cup has an angularly adjustable mechanism. A modular version of the headrest and a kit storing the headrest are also described.

Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions comprising same, for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, are also provided.

Abstract: Disclosed are sweetened consumables and methods of forming said sweetened consumables that comprise certain sweeteners and at least one sweetness enhancer in a concentration near its sweetness detection threshold. The sweeteners include sucrose, fructose, glucose, high fructose corn syrup, corn syrup, xylose, arabinose, rhamnose, erythritol, xylitol, mannitol, sorbitol, inositol, acesulfame potassium, aspartame, neotame, sucralose, saccharine, or combinations thereof. The sweetness enhancer is selected from naringin dihydrochalcone, mogroside V, swingle extract, rubusoside, rubus extract, rebaudioside, and stevioside.

Abstract: A testable back pressure valve can include a housing comprising a housing body. The valve can also include a valve seat coupled to the housing, where the valve seat includes a valve seat body having a first cavity and a second cavity, and where the valve seat further includes a first network of channels disposed in the valve seat body. The valve can further include a valve head movably disposed within the first cavity of the valve seat. The valve can also include a piston follower movably disposed within the second cavity of the valve seat, where the valve head is fixedly coupled to the piston follower. The valve can further include a travel piston movably disposed within the second cavity of the valve seat, where the travel piston is moveably coupled to the piston follower.

Abstract: Disclosed are sweetened consumables and methods of forming said sweetened consumables that comprise certain sweeteners and at least one sweetness enhancer in a concentration near its sweetness detection threshold. The sweeteners include sucrose, fructose, glucose, high fructose corn syrup, corn syrup, xylose, arabinose, rhamnose, erythritol, xylitol, mannitol, sorbitol, inositol, acesulfame potassium, aspartame, neotame, sucralose, saccharine, or combinations thereof. The sweetness enhancer is selected from naringin dihydrochalcone, mogroside V, swingle extract, rubusoside, rubus extract, rebaudioside, and stevioside.

Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.

Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: A testable back pressure valve can include a body. The valve can also include a first flow regulating device movably disposed within a top end of the body, where the first flow regulating device is configured to move from a first default position to a first position based on first flow characteristics of a first fluid that flows into a top end of the body toward a bottom end of the body. The valve can further include a second flow regulating device movably disposed within the bottom end of the body. The valve can also include a network of channels disposed within the body between the first flow regulating device and the second flow regulating device.

Abstract: Disclosed are sweetened consumables and methods of forming said sweetened consumables that comprise certain sweeteners and at least one sweetness enhancer in a concentration near its sweetness detection threshold. The sweeteners include sucrose, fructose, glucose, high fructose corn syrup, corn syrup, xylose, arabinose, rhamnose, erythritol, xylitol, mannitol, sorbitol, inositol, acesulfame potassium, aspartame, neotame, sucralose, saccharine, or combinations thereof. The sweetness enhancer is selected from naringin dihydrochalcone, mogroside V, swingle extract, rubusoside, rubus extract, rebaudioside, and stevioside.

Abstract: The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

Abstract: The present disclosure relates to amorphous and crystalline forms of (R)—N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoro-quinolin-4-yl) cyclohexyl)propanamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.

Abstract: Compounds that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.

Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: A multi-well pad for fracturing a subterranean formation can include a valve assembly that includes a shuttle valve, an inlet, a first outlet, and a second outlet, where the inlet is coupled to a fracturing pump, where the first outlet is coupled to a first well, where the second outlet is coupled to a second well, where first shuttle valve has a first position and a second position. The fracturing pump and the first well can form a continuous first path through the valve assembly while closing off a second path between the fracturing pump and the second well when the shuttle valve is in the first position. The fracturing pump and the second well can form a continuous second path through the valve assembly while closing off the first path between the fracturing pump and the first well when the shuttle valve is in the second position.

Abstract: Disclosed are sweetened consumables and methods of forming said sweetened consumables that comprise certain sweeteners and a compound of formula (1), wherein R1 is selected from the group consisting of OH and OCH3, and R2 is selected from the group consisting of H and OH, R1 and R2 comprise at least one OH group, and when R1 is OH then R2 is H (trilobatin), and when R1 is OCH3 then R2 is OH (HDG), in a concentration near its sweetness detection threshold. The sweeteners include sucrose, fructose, glucose, high fructose corn syrup, corn syrup, xylose, arabinose, rhamnose, erythritol, xylitol, mannitol, sorbitol, inositol, acesulfame potassium, aspartame, neotame, sucralose, saccharine, or combinations thereof.

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: Disclosed are sweetened consumables and methods of forming said sweetened consumables that comprise certain sweeteners and a compound of formula (1), wherein R1 is selected from the group consisting of OH and OCH3, and R2 is selected from the group consisting of H and OH, R1 and R2 comprise at least one OH group, and when R1 is OH then R2 is H (trilobatin), and when R1 is OCH3 then R2 is OH (HDG), in a concentration near its sweetness detection threshold. The sweeteners include sucrose, fructose, glucose, high fructose corn syrup, corn syrup, xylose, arabinose, rhamnose, erythritol, xylitol, mannitol, sorbitol, inositol, acesulfame potassium, aspartame, neotame, sucralose, saccharine, or combinations thereof.

Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.